• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down 2.84% Nasdaq Down 2.94%

    Alnylam Pharmaceuticals, Inc. (ALNY)

    -NasdaqGS
    97.90 Down 5.01(4.87%) Sep 1, 4:00PM EDT
    Add to Portfolio
    Prev Close:102.91
    Open:100.14
    Bid:11.11 x 800
    Ask:115.50 x 100
    1y Target Est:146.82
    Beta:2.0059
    Earnings Date:Nov 3 - Nov 9 (Est.)
    Day's Range:97.50 - 102.49
    52wk Range:63.48 - 140.00
    Volume:896,571
    Avg Vol (3m):760,546
    Market Cap:8.28B
    P/E (ttm):N/A
    EPS (ttm):-2.35
    Div & Yield:N/A (N/A)
    Quotes delayed, except where indicated otherwise. Currency in USD.

    Related Video

    Headlines

    » More Headlines for ALNY

    Comparison

    Symbol% ChgMkt Cap
    ALNYDown 4.87%8.28B
    PFEDown 2.67%193.41B
    MRKDown 2.45%147.96B

    Key Statistics

    Forward P/E (1 yr):N/A
    P/S (ttm):139.78
    Ex-Dividend Date:N/A

    Analysts

    Annual EPS Est (Dec-15) :-3.27
    Quarterly EPS Est (Sep-15) :-0.92
    Mean Recommendation*:2.0
    PEG Ratio (5 yr expected):-0.65

    * (Strong Buy) 1.0 - 5.0 (Sell)

    Analyst Opinion | Estimates

    Business Summary

    Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase ... View More
    Your browser doesn't support canvas
    SETTINGS
    Scrolling
    Speed
    Display
    Price
    Submit Feedback